GLPwatch
Semaglutide: A New Medical Swiss Army Knife?
J Cardiothorac Vasc Anesth · 2024
Last updated 2026-05-28| Journal | J Cardiothorac Vasc Anesth, 2024 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.45 |
| NIH percentile | 27 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease, Mash, Obstructive Sleep Apnea, Pcos, Heart Failure, Alcohol Use Disorder, Smoking Cessation, Depression, Anxiety, Fertility, Gastroparesis |
Full record and abstract on PubMed 38246820 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.